COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00277316
Recruitment Status : Terminated (Development of XL999 was stopped due to cardiac toxicities in the subjects)
First Posted : January 16, 2006
Last Update Posted : February 19, 2010
Information provided by:
Symphony Evolution, Inc.

Brief Summary:
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Drug: XL999 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma
Study Start Date : December 2005
Actual Primary Completion Date : February 2007
Actual Study Completion Date : June 2007

Intervention Details:
  • Drug: XL999
    Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.

Primary Outcome Measures :
  1. Response rate [ Time Frame: Inclusion until disease progression ]
  2. Safety and tolerability [ Time Frame: Inclusion until 30 days post last treatment ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: Inclusion until disease progression ]
  2. Duration of response [ Time Frame: Inclusion until disease progression ]
  3. Overall survival [ Time Frame: Inclusion until 180-day Follow-up post last treatment or death ]
  4. Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters [ Time Frame: Blood samples for PK/PD analysis will be obtained at the end of infusion for the first 8 weeks of treatment. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females with histologically confirmed metastatic clear cell RCC
  • Measurable disease according to Response Criteria for Solid Tumors (RECIST)
  • No prior systemic cytotoxic chemotherapy
  • Subjects who have received either no prior therapy for RCC, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting VEGF or a VEGFR (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled
  • ECOG performance status of 0 or 1
  • Life expectancy ≥3 months
  • Adequate organ and marrow function
  • No other malignancies within 5 years
  • Signed informed consent

Exclusion Criteria:

  • Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
  • Subjects who have received systemic anticancer therapy within 30 days of XL999 treatment
  • Subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered >30 days prior to study enrollment
  • History of or known brain metastases, current spinal cord compression or carcinomatous meningitis
  • Uncontrolled and/or intercurrent illness
  • Pregnant or breastfeeding females
  • Known HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00277316

Layout table for location information
United States, California
Department of Hematology/Oncology
Los Angeles, California, United States, 90095
Stanford Cancer Center
Palo Alto, California, United States, 94305
United States, Florida
Integrated Community Oncology Network
Jacksonville, Florida, United States, 32256
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Joliet Oncology-Hematology Associates, Ltd
Joliet, Illinois, United States, 60435
United States, Indiana
Division of Hematology/Oncology, Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Ohio
The Cleveland Clinic Foundation Taussig Cancer Center
Cleveland, Ohio, United States, 44195
United States, Texas
Center for Oncology Research and Treatment, PA
Dallas, Texas, United States, 75230
The Center for Cancer and Blood Disorders
Fort Worth, Texas, United States, 76104
Sponsors and Collaborators
Symphony Evolution, Inc.
Layout table for investigator information
Study Director: Lynne A. Bui, MD Exelixis
Layout table for additonal information
Responsible Party: Charles W. Finn, PhD, President and CEO, Symphony Evolution, Inc. Identifier: NCT00277316    
Other Study ID Numbers: XL999-201
First Posted: January 16, 2006    Key Record Dates
Last Update Posted: February 19, 2010
Last Verified: February 2010
Keywords provided by Symphony Evolution, Inc.:
Kidney cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases